EN DE

Davide Campari-Milano N.V (CPR) Fair Value & Analysis

Consumer Defensive · IT · Market cap €6.5B

DC Davide Campari-Milano N.V CPR · MI
Price€5.95
Fair Value€5.01
Upside-15.8%
Quality54/100
Watch Davide Campari-Milano N.V for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Solidly profitable · 11.4% net margin
Moderate debt · generates free cash flow
1.84% dividend yield
Trails peers (5/15)
Moderate moat 52/100
Evidence: High Range €2.82 – €7.58 Share as image

Fair value as of: Jul 15, 2026

From 24 valuation models · updated 26 days ago

Share price +6.5% over the past month.

A solid business, but screening 16% overvalued on our models.

What matters now

  • The model range is unusually wide (€2.82 to €7.58). The outcome hinges heavily on assumptions, so read the point estimate with caution.
  • Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

€12.88 €5.01 Fair Value €5.01 May 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 15, 2026.

How to read this chart

60‑month range €5.01 – €12.88 · fair‑value band €2.82 – €7.58 · the €5.95 price screens above the €5.01 fair value. Dashed = 300-day average. As of Jul 15, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Davide Campari-Milano N.V (CPR) currently trades at €5.95, while our model-based Fair Value estimate is €5.01, implying the stock looks roughly 15.8% overvalued today. The Quality Score stands at 54/100 (solid quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Davide Campari-Milano N.V generated revenue of €3.1B at a net margin of 11.4%. Revenue declined 2.8% year over year. It earns a return on equity of 8.6%. Net debt stands at €1.8B. Fundamentals as of Jul 15, 2026

Our scenario range runs from €2.82 (bear case) to €7.58 (bull case); at €5.95, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 12% below its 52-week high and 14% above its 52-week low, currently above its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at 6% fair-value upside, at -16%, CPR screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF €2.26 €3.83 €5.97 80
Residual Income €2.71 €2.94 €3.68 76
Rev-Margin DCF €1.61 €3.17 €4.96 74
All 24 models by family
DCF Models
FCF DCF €2.21 €3.98 €6.55 38
Owner Earnings €0.4800 €1.37 €2.67 31
5Y Revenue Exit €1.61 €3.15 €5.07 39
5Y EBITDA Exit €3.44 €6.55 €10.16 41
5Y P/E Exit €2.57 €4.92 €7.36 38
10Y Revenue Exit €1.73 €3.15 €5.01 36
10Y EBITDA Exit €2.94 €5.46 €8.79 37
10Y P/E Exit €2.40 €4.35 €6.71 35
Earnings-Based
Graham-Dodd €1.96 €5.94 €7.87 54
Lynch FV €1.27 €1.81 €2.35 50
PEG = 1.0 €1.27 €1.81 €2.35 46
EPV €2.83 €3.47 €4.03 59
Multiples
P/E Multiple €4.55 €6.07 €7.58 63
P/S Multiple €3.05 €4.07 €5.09 58
P/B Multiple €3.68 €4.91 €6.14 55
EV/EBIT €5.14 €7.28 €9.42 53
EV/EBITDA €4.84 €6.88 €8.91 54
EV/Revenue €1.41 €2.55 €3.70 43
Asset-Based
NCAV (Graham) €1.61 €2.16 €3.22 50
Growth DCF
Growth DCF €2.26 €3.83 €5.97 80
Rev-Margin DCF €1.61 €3.17 €4.96 74
Economic Profit
Residual Income €2.71 €2.94 €3.68 76
ROIC Compounder €2.83 €3.61 €4.74 72
Growth Earnings
Growth-Adj P/E €3.72 €5.32 €6.92 68

Widest divergence: Growth Earnings (€5.32) versus Earnings-Based (€1.81). Highest evidence: Growth DCF (80).

Notify me when CPR reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) €3.1B
Revenue growth (YoY) -2.8%
Net margin 11.4%
Return on equity 8.6%
Free cash flow €388M FY2025
P/E ratio 18.8
More key figures
Operating margin 17.4%
EPS (TTM) €0.2900
Dividend yield 1.8%
EPS growth (YoY) +36.3%
Net debt €1.8B FY2025

Figures from reported company fundamentals · as of Jul 15, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 54/100

Of which business quality 54 · Market factors (momentum, volatility) 47

Profitability 39
Margins and returns on capital today
Quality Growth 44
Are margins and returns improving?
Cashflow 68
Earnings quality: real cash, not paper profit
Fin. Strength 55
Balance sheet, leverage, solvency risk
Investment 46
Disciplined investing over empire-building
Low Volatility 79
Calm price path (market factor)
Momentum 31
Price trend over the last 3–12 months (market factor)
52W Momentum 37
Distance to the 52-week high (market factor)
Net Issuance 74
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Davide Campari-Milano N.V., together with its subsidiaries, trades in alcoholic and non-alcoholic beverages in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific.

Full company description

Davide Campari-Milano N.V., together with its subsidiaries, trades in alcoholic and non-alcoholic beverages in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. It offers a range of products, including aperitifs, vodka, whisky, rum, agave, cognac, and champagne under the Aperol, Campari, Picon, Cynar, Sarti Rosa, Campari Soda, Crodino, Aperol Spritz RTE, Wild Turkey, Appleton Estate, Wray and Nephew, The GlenGrant, Wilderness Trail, Espolòn, Ancho Reyes, Montelobos, Grand Marnier, Courvoisier, Bisquit, Champagne Lallier, SKYY Vodka, Bulldog Gin, Averna, Braulio, Forty Creek, Frangelico, Cabo Wabo, Del Professore, Mondoro, Riccadonna, La Mauny, Trois Rivieres, Kingston 62, O'ndina, Bickens, Dreher, Ouzo 12, Sagabita, and Zedda Piras brand names. Davide Campari-Milano N.V. was founded in 1860 and is headquartered in Sesto San Giovanni, Italy. Davide Campari-Milano N.V. operates as a subsidiary of Lagfin S.C.A.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Davide Campari-Milano N.V reported revenue of €3.1B in FY2025 versus €2.2B in FY2021, a compound +8.9%/yr. Reported net income was €346M in FY2025, compounding +5.0%/yr from FY2021.

Growth Quality 83/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
€3.1B
Latest YoY
−0.6%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.2%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+11.5%
Avg. growth/yr (22Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+5.8%
Revenue +8.9%/yr
FY21 €2.2B
FY22 €2.7B
FY23 €2.9B
FY24 €3.1B
FY25 €3.1B
Net income +5.0%/yr
FY21 €285M
FY22 €333M
FY23 €331M
FY24 €202M
FY25 €346M
Character of growth · EPS growth decomposed (2013-2024) +7.5 % p.a.
Revenue per share +7.0 pp

of which total revenue +7.0 pp · buybacks/dilution +0.1 pp

EBIT margin −0.9 pp
Tax rate +0.7 pp
Residual (interest, one-offs) +0.7 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

CPR screens 16% overvalued. Compare with Kweichow Moutai Co →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Davide Campari-Milano N.V Fair Value". https://www.fairvalue-calculator.com/stock/CPR

Peer Group

Beverages - Wineries & Distilleries · 96 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 54 · Below median
Fair Value upside −16% · Below median
Return on equity (TTM) 9% · Above median
Return on assets 5% · Above median
Net margin (TTM) 11% · Above median
Operating margin (TTM) 17% · Above median
Revenue growth -3% · Below median
Dividend yield (TTM) 1.8% · Below median
Debt / equity 0.57× · Higher than 75% of peers

Valuation Multiples vs Beverages - Wineries & Distilleries median · lower = cheaper

P/E (TTM) 18.8× · Cheaper than median
P/B 1.95× · Pricier than median
P/S (TTM) 2.47× · Pricier than median
P/FCF 19.4× · Pricier than 75% of peers
EV/EBITDA 12.1× · Pricier than median
PEG 1.62× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 12 · sector 17
FUTURE 0 · sector 0
PAST 35 · sector 17
HEALTH 71 · sector 95
DIVIDEND 37 · sector 61

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Alcohol

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Beverages - Wineries & Distilleries stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).

Stock Price Fair Value vs Fair Value
Kweichow Moutai Co 600519 ¥1,251 ¥1,238 -1%
Diageo plc DEON 1,487 MXN 1,239 MXN -17%
Wuliangye Yibin Co 000858 ¥73.69 ¥48.44 -34%
Shanxi Xinghuacun Fen Wine Factory Co 600809 ¥110.50 ¥185.80 +68%
Pernod Ricard SA RI €65.24 €76.68 +18%
Luzhou Laojiao Co 000568 ¥83.12 ¥149.17 +79%
Brown-Forman Corporation BFA $26.60 $28.15 +6%
United Spirits Limited UNITDSPR ₹1,376 ₹440.56 -68%
Thai Beverage Public Company Y92 0.4450 SGD 0.6900 SGD +55%
Jiangsu Yanghe Distillery Co 002304 ¥38.08 ¥27.82 -27%

Compare Davide Campari-Milano N.V with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Davide Campari-Milano N.V (CPR) overvalued or undervalued?
As of Jul 15, 2026, our model estimates a fair value of €5.01 versus a price of €5.95, about −16% (overvalued).
What is the fair value of CPR?
Our model-based fair value for Davide Campari-Milano N.V is €5.01 (as of Jul 15, 2026), built from audited fundamentals. The current price is €5.95.
What is the quality score of CPR?
Davide Campari-Milano N.V has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Davide Campari-Milano N.V (CPR)?
Davide Campari-Milano N.V reported trailing-twelve-month revenue of about €3.1B (latest available figure, as of Jul 15, 2026).
What is the net profit margin of CPR?
The net profit margin of Davide Campari-Milano N.V is about 11.4%, meaning it keeps roughly 11.4% of revenue as net income. Based on the latest reported figures.
Does Davide Campari-Milano N.V pay a dividend?
Davide Campari-Milano N.V currently shows a dividend yield of about 1.84% relative to its recent price (as of Jul 15, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Davide Campari-Milano N.V and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.